Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?

Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?
May 25, 2021

In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards. They will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:

  • The SPC manufacturing waiver
  • The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
  • The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
  • The General Court’s very recent Polpharma ruling on Data Exclusivity

Contact

  • Kirian Claeyé

    Partner

Recommended articles

June 05, 2025

Category Captains beware!: Belgian competition authority fines Category Management of OTC medicines

On 24 April 2025, the Belgian Competition Authority (BCA) announced a landmark decision imposing fines totaling over €11.2 million on three major pharmaceutical companies for their involvement in a long-running anti-competitive arrangement concerning the placement of over-the-counter (OTC) medicines in Belgian pharmacies..

Read on
March 17, 2025

The new Belgian government’s public health policy: 10 key take-aways for pharma policy

The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.

Read on
March 13, 2025

CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?

The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.

Read on